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ABSTRACT
Thirty-ﬁve Bacteroides fragilis clinical isolates with
varying susceptibility to meropenem were analy-
sed with a prototype of a double-ended Etest strip
containing meropenem ± EDTA, designed for the
detection of the CﬁA metallo-b-lactamase. Pheno-
typic results obtained with this new Etest strip
were related to the genotype and compared to the
results of the Etest containing imipenem ± EDTA.
Whereas the Etest with imipenem ± EDTA only
allowed detection of isolates with high-level
resistance (both MICs of imipenem and merope-
nem >32 mg ⁄L), reﬂecting the possible underes-
timation of CﬁA prevalence in B. fragilis, the Etest
with meropenem ± EDTA proved to be more
accurate, particularly for isolates with low-level
carbapenem resistance, suggesting its potential
for broader detection of CﬁA production.
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Bacteroides fragilis is an important anaerobic path-
ogen commonly associated with polymicrobial
infections. Carbapenems are normally highly
active against B. fragilis. However, carbapenem-
resistant B. fragilis isolates have been reported
[1–15], mainly because of the production of CﬁA,
a class B metallo-b-lactamase (MBL) present in up
to 7% of those isolates [3,4]. This enzyme is
usually poorly expressed, but the insertion of
a variety of insertion sequence (IS) elements
upstream of cﬁA, subsequent to a single genetic
event selected with carbapenems [11,16], switches
on gene expression and leads to high-level carb-
apenem resistance [4,5,11–16]. Thus, it is impor-
tant to detect all B. fragilis isolates that harbour
the cﬁA gene in order to avoid inappropriate
carbapenem usage, which may result in the
selection and emergence of high-level resistance
in these strains. In that respect, enzymatic studies
of CﬁA [17] have shown that meropenem is a
better substrate than imipenem for this MBL of
B. fragilis.
The aim of this preliminary study was to assess
the potential value of a novel Etest strip contain-
ing meropenem ± EDTA to detect carbapenem
resistance due to CﬁA in B. fragilis.
Thirty-ﬁve B. fragilis clinical isolates were
examined. Seventeen of these, displaying either
reduced susceptibility (MIC: >1 and £4 mg ⁄L) or
resistance (MIC: >8 mg ⁄L) to meropenem, were
obtained from different microbiology laboratories
between 2005 and 2007 as part as of a multicentre
survey [2]. Eighteen clinically relevant B. fragilis
isolates susceptible to meropenem (MIC:
<1 mg ⁄L) were collected during 2005 at the
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Mont-Godinne University hospital, and B. fragilis
ATCC25285 (carbapenem-susceptible) was
included as a negative control.
Etest determinations of the MICs of imipenem
and meropenem (MIC ranges: 0.002 to >32 mg ⁄L)
were performed on Brucella Agar (Becton-Dick-
inson, Edembodegem, Belgium) supplemented
with 5% deﬁbrinated horse blood plus haemin
(5 mg ⁄L) and menadione (1 mg ⁄L). All cultures
were grown for 24–48 h, and individual colonies
were picked and suspended in Brucella broth to
reach a ﬁnal inoculum matching the turbidity
of a 1 McFarland standard (c.108 CFU ⁄mL). Plates
were inoculated by streaking with a cotton swab,
and dried before the Etest strips were applied.
Incubation took place in an anaerobic atmosphere
using the Anoxomat system (MART, Microbiol-
ogy, B.V., Lichtenvoorde, The Netherlands) at
35C for 24 and 48 h.
Phenotypic detection of MBL was done
with two double-ended Etest strips, with
the following gradient formulations: imipenem
(4–256 mg ⁄L) ⁄ imipenem + EDTA (1–64 mg ⁄L),
and meropenem (0.25–16 mg ⁄L) ⁄meropenem +
EDTA (0.064–4 mg ⁄L); the same set-up procedure
as that described for MIC testing was used. A
reduction of the carbapenem MIC by ‡3 dilutions
in the presence of EDTA (MIC ratio ± EDTA of
‡8), or the presence of a ‘phantom zone’, or
deformation of the inhibition ellipse, was inter-
preted as positive for MBL production according
to instructions from the manufacturer.
PCR analysis was performed to conﬁrm the
presence of cﬁA and to detect the presence of an IS
using the primers and conditions described by
Yamazoe et al. [15].
For B. fragilis isolate no. 3, three additional
primers (ISPodFW, 5¢-aag ccc tgc ctg cca tta tg-3¢
Table 1. Phenotypic and genotypic characterization of carbapenem resistance in Bacteroides fragilis strains
Strain MIC (mg ⁄L) PCR sequencing
Imipenem MBL Etest (MIC,
mg ⁄L)
Meropenem MBL Etest (MIC,
mg ⁄L)
No. Code IP MP cﬁA
cﬁA
promoter (kb)
IS
identiﬁcation IP IP + EDTA MBLa MP MP + EDTA MBLa
1 N6081749 >32 >32 + 2 IS 612-like >256 2 + >16 >4 ID
2 CQ7021 >32 >32 + 2 IS 614c-like >256 1 + >16 >4 ID
3 05 ⁄ 0113 >32 >32 + Neg.b IDb 96 <1 + >16 0.38 +
4 06 ⁄ 1121 >32 >32 + 0.4 None 24 <1 + >16 0.125 +
5 06 ⁄ 1152 3 >32 + 0.4 None <4 <1 ID >16 0.125 +
6 E40 3 >32 + 0.4 None <4 1 ) >16 0.25 +
7 I24 4 >32 + 0.4 None <4 <1 ID >16 0.19 +
8 I3 0.094 16 + 0.4 None <4 1 ) >16 0.19 +
9 H28 1 12 + 0.4 None <4 1 ) >16 0.19 +
10 I63 1 12 + 0.4 None <4 <1 ID >16 0.19 +
11 I73 0.094 6 + 0.4 None <4 <1 ID >16 0.19 +
12 06 ⁄ 0938 0.094 4 + 0.4 None <4 <1 ID >16 0.125 +
13 B67 0.094 3 + 0.4 None <4 <1 ID 4 0.094 +
14 N5013118 0.25 4 + 0.4 None <4 <1 ID >16 0.125 +
15 C22 0.094 4 + 0.4 None <4 <1 ID 4 0.19 +
16 14179459 2 12 ) NA NA <4 <1 ID >16 >4 IDc
17 F32 0.38 3 ) NA NA <4 <1 ID 4 >4 )
18 N4102647 0.19 0.19 ) NA NA <4 <1 ID 0.38 0.19 )
19 N4102724 0.064 0.094 ) NA NA <4 <1 ID 0.125 0.094 )
20 N4111382 0.094 0.125 ) NA NA <4 <1 ID 0.125 0.094 )
21 N4111975 0.125 0.094 ) NA NA <4 <1 ID 0.125 0.064 )
22 N4112438 0.094 0.125 ) NA NA <4 <1 ID 0.125 0.094 )
23 N4122106 0.125 0.125 ) NA NA <4 <1 ID 0.125 0.094 )
24 N5012367 0.047 0.125 ) NA NA <4 <1 ID 0.125 0.064 )
25 N5021171 0.38 0.19 ) NA NA <4 <1 ID 0.19 0.125 )
26 N5023073 0.125 0.19 ) NA NA <4 <1 ID 0.125 0.064 )
27 N5031703 0.094 0.125 ) NA NA <4 <1 ID 0.125 0.064 )
28 N5032419 0.125 0.19 ) NA NA <4 <1 ID 0.094 0.064 )
29 N5042513 0.125 0.125 ) NA NA <4 <1 ID 0.125 0.064 )
30 N5042538 0.047 0.125 ) NA NA <4 <1 ID 0.125 0.094 )
31 N5060881 0.064 0.094 ) NA NA <4 <1 ID 0.094 0.064 )
32 N5062809 0.19 0.25 ) NA NA <4 <1 ID 0.25 0.125 )
33 N5071437 0.094 0.125 ) NA NA <4 <1 ID 0.125 0.094 )
34 N5083380 0.19 0.5 ) NA NA <4 <1 ID 0.5 0.38 )
35 N5083465 0.25 0.125 ) NA NA <4 <1 ID 0.125 0.064 )
36 ATCC 25285 0.032 0.125 ) NA NA <4 <1 ID 0.125 0.094 )
IP, imipenem; MP, meropenem; IS, insertion sequence; MBL, metallo-b-lactamase; ID, indeterminate; NA, not analysed.
aDeduced presence or absence of MBL.
bMultiple repeats with various primer pairs failed to amplify any promoter-containing sequence.
cID results at 48 h (negative at 24 h). Full range strip MP ⁄MP + EDTA conﬁrmed the negative result.
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[16]; ISG2FW, 5¢-gtt tcg acc ggg aga cca tcc tc-3¢;
ISupFW, 5¢-acc aaa gac gtg cct cct ta-3¢) were
used in order to obtain the full promoter of cﬁA.
Ampliﬁcation products were sequenced on an
ABI 3100 Genetic analyzer (Applied Biosystems,
Foster City, CA, USA) with primers used for PCR
detection.
Among 17 B. fragilis clinical isolates that were
initially found to be non-susceptible to merope-
nem (Table 1), eight were conﬁrmed as being
resistant according to the CLSI breakpoints (MIC:
‡16 mg ⁄L) [18], four showed an intermediate
level of resistance (MIC: 6–12 mg ⁄L) and ﬁve
were borderline susceptible (MIC: 3–4 mg ⁄L). The
MIC50 value of meropenem for these B. fragilis
strains was 12 mg ⁄L (ranging between 3 and
>32 mg ⁄L). By contrast, only four of the 17
meropenem non-susceptible B. fragilis isolates
displayed high-level resistance to imipenem
(MIC: >32 mg ⁄L). On the other hand, the 13
remaining isolates were categorized as suscepti-
ble (MIC range: 0.094–4 mg ⁄L) according to the
CLSI susceptibility breakpoints recommended for
imipenem. The 18 carbapenem-susceptible B. fra-
gilis isolates displayed similar MIC ranges (0.047–
0.5 mg ⁄L) and MIC50 values (MIC: 0.125 mg ⁄L)
for both carbapenems.
The presence of cﬁA was conﬁrmed in 15 of the
17 strains with meropenem MICs ‡3 mg ⁄L. Two
strains with moderately elevated meropenem
MICs (3 and 12 mg ⁄L) were found to be cﬁA-
negative even after repeated PCR testing (data not
shown). The fact that these two strains were
found to be cﬁA-negative cannot, however,
exclude the presence of unidentiﬁed carbapene-
mases or rule out any other resistance mecha-
nisms (e.g. cephalosporinase overproduction
combined with porin deﬁciency or alterations in
penicillin-binding proteins). By contrast, cﬁA was
not found in any of the 18 control carbapenem-
susceptible B. fragilis isolates.
Among the four B. fragilis isolates that were
highly resistant both to meropenem and to imip-
enem (MICs: >32 mg ⁄L), two possessed a cﬁA-
associated IS element inserted in the promoter
regions (as detected in amplicons of 2 kb).
Sequencing revealed that these elements were
closely related to IS612 in one case (isolate no. 1)
and to IS614 in the second isolate (isolate no. 2). In
one isolate (no. 3), repetitive attempts failed to
amplify any promoter-containing fragment (PCR-
negative), andno ISwasdetected (0.4-kb amplicon)
in isolate no. 4. Sequencing of the promoter and
cﬁA gene of strain no. 4 did not reveal any differ-
ence in nucleotide sequence as compared with a
fully carbapenem-susceptible isolate (data not
shown). Interestingly, IS elements could not be
detected in the cﬁA promoter regions in any of the
B. fragilis strains with imipenem MICs <32 mg ⁄L.
Phenotypic results obtained with the double-
ended Etest strips showed that the new Etest
meropenem ± EDTA MBL strip allowed the
detection of 13 of 15 cﬁA-positive isolates (sensi-
tivity 87%). For two isolates with MIC values
>32 mg ⁄L for imipenem and for meropenem,
the Etest meropenem strip results were out of
range and were reported as indeterminate (mero-
penem > 16 ⁄meropenem + EDTA > 4 mg ⁄L). On
the other hand, the imipenem ± EDTA strip
allowed MBL detection in only four isolates
(no. 1, no. 2, no. 3, no. 4; sensitivity 27%), which
all displayed high MIC values (>32 mg ⁄L) for
both carbapenems; these also included the two
isolates reported as indeterminate using the
meropenem ± EDTA strip.
In the original validation study of Walsh et al.
[19], the sensitivity of the imipenem ± EDTA strip
appeared to be excellent for the detection of CﬁA,
but all ten of the imipenem-resistant B. fragilis
strains tested showed MIC values above 4 mg ⁄L,
and no MIC data were reported for meropenem.
Among the 21 cﬁA-negative strains, 20 were
correctly detected as negative using the merope-
nem ± EDTA strip (speciﬁcity 95%), whereas the
imipenem ± EDTA strip yielded inconclusive
results for all strains because the MIC values
were systematically off-scale, i.e. below the lowest
concentrations for imipenem and imipenem +
EDTA.
According to these results, the use of the
meropenem ± EDTA strips may be recom-
mended to ensure accurate detection of CﬁA-
producing B. fragilis strains, especially those with
low-level enzyme production. In cases of off-scale
results caused by high-level resistance (merope-
nem MIC: >32 mg ⁄L), the use of the imipe-
nem ± EDTA strip could then be recommended
as a second step.
Additional validation studies, including imip-
enem ⁄meropenem hydrolysis experiments, with a
larger number of well-characterized carbapenem-
resistant B. fragilis isolates originating from dif-
ferent sources, will be required, however, to
conﬁrm the results of this preliminary study.
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Moreover, MBL-producing Enterobacteriaceae (e.g.
VIM-type-producing or IMP-type-producing iso-
lates) displaying decreased susceptibility to imi-
penem but with MICs usually lower than 4 mg ⁄L
are now increasingly being reported [20]. It is
anticipated that such strains will also be difﬁcult
to detect with the current Etest strip based
on imipenem ± EDTA, because of the high con-
centration range used in this test (4–256 mg ⁄L)
[20]. The concentration range of meropenem
(0.25–16 mg ⁄L) used in the new Etest merope-
nem ± EDTA prototype might be better suited for
phenotypic detection of MBLs in isolates of
Enterobacteriaceae.
Overall, these results suggest that the detection
of the CﬁA MBL in B. fragilis may be substantially
improved by the use of the meropenem ± EDTA
prototype strip as compared to the currently
available Etest imipenem ± EDTA strip. Addi-
tional investigations using a broader panel of
bacterial genera or species characterized as MBL
producers are also recommended, and should be
carried out to back up the present results.
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ABSTRACT
Carbapenem-resistant Acinetobacter baumannii
(CR-Ab) ranked third, with a frequency of 24.8%,
among 202 strains of multidrug-resistant bacteria
isolated from clinical samples in the main hospital
of New Caledonia in 2004. All CR-Ab isolates were
analysed by isoelectric focusing, conjugation,
pulsed-ﬁeld gel electrophoresis and PCR for the
presence of carbapenemase genes. Fifty CR-Ab
isolates produced carbapenemase OXA-23. The
isolates belonged to a single clone presenting
several subtypes, suggesting an endemic situation.
This study further illustrates the widespread
prevalence of carbapenemase OXA-23-producing
CR-Ab isolates in the South Paciﬁc.
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Acinetobacter baumannii has emerged worldwide
as an important nosocomial pathogen, causing
outbreaks particularly in intensive care units, in
wards with patients who have serious underlying
illness, and in warm countries [1]. Imipenem is
among the drugs of choice for treatment of
nosocomial infections due to multidrug-resistant
(MDR) A. baumannii isolates. However, their efﬁ-
cacy is being increasingly compromised by the
emergence of carbapenem-hydrolysing b-lacta-
mases of molecular Ambler class B (VIM, IMP)
and class D (OXA-23, OXA-58) [1].
The aim of this study was to analyse the
molecular mechanisms of carbapenem resistance
in A. baumannii and to evaluate carbapenem-
resistant A. baumannii (CR-Ab) prevalence among
all MDR strains isolated at the central hospital of
Noumea (CHT), a 285-bed tertiary-referral centre.
Methicillin-resistant Staphylococcus aureus,
vancomycin-resistant Enterococcus and all Gram-
negative bacteria resistant to at least three agents
from distinct classes of antibiotics, including
extended-spectrum cephalosporin-resistant
Enterobacteriaceae, ceftazidime-resistant Pseudomo-
nas aeruginosa, CR-Ab, ceftazidime-resistant Burk-
holderia spp., and clavulanate–ticarcillin-resistant
Stenotrophomonas maltophilia, were considered to
be MDR. The study was conducted during the
entire year 2004 in the CHT. During that period,
15 320 patients were admitted. All MDR bacteria
included were from clinical samples. Colonization
and environmental samples were excluded. Only
the ﬁrst sample was analysed for patients who
had more than one MDR bacterial episode involv-
ing the same strain during the year of the study.
The incidence of MDR bacteria acquisition is
expressed as the number of MDR bacteria acqui-
sitions per 1000 patient-days in the hospital.
Standard bacteriological techniques and an
automated BacT ⁄Alert system (bioMe´rieux,
Marcy l’Etoile, France) were used to culture
bacteria. Bacterial isolates were initially identiﬁed
by various routine microbiological methods [2].
Identiﬁcation of A. baumannii isolates was con-
ﬁrmed by the detection and sequencing of the
intrinsic blaoxa-51-like gene [3]. Susceptibility of the
isolates to common antibacterial agents was
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